Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Recommendation of "Buy" by Brokerages

Key Points

• Amneal Pharmaceuticals has received a consensus rating of "Buy" from five analysts, with an average price target of $11.60.
• Insider trading activity includes significant sales by executives, with EVP Jason B. Daly selling 22,000 shares and EVP Nikita Shah selling 71,694 shares, representing decreases of 67.47% and 21.15% in their positions, respectively.
• Vanguard Group and Rubric Capital Management are among several institutional investors that have increased their holdings in Amneal Pharmaceuticals, indicating ongoing confidence in the company's prospects.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been assigned a consensus rating of "Buy" from the five ratings firms that are presently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $11.60.

Several equities analysts have commented on the stock. The Goldman Sachs Group assumed coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Jason B. Daly sold 22,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at approximately $95,984.30. The trade was a 67.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nikita Shah sold 71,694 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $9.29, for a total transaction of $666,037.26. Following the sale, the executive vice president directly owned 267,235 shares in the company, valued at $2,482,613.15. This trade represents a 21.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 456,374 shares of company stock valued at $4,239,042. 26.56% of the stock is owned by insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in AMRX. GAMMA Investing LLC grew its holdings in shares of Amneal Pharmaceuticals by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock valued at $26,000 after purchasing an additional 3,107 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $31,000. Amalgamated Bank boosted its position in Amneal Pharmaceuticals by 33.0% during the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $52,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Amneal Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,107 shares of the company's stock worth $98,000 after buying an additional 1,735 shares during the period. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Trading Up 0.6%

AMRX stock traded up $0.06 during mid-day trading on Wednesday, hitting $9.59. The stock had a trading volume of 1,720,973 shares, compared to its average volume of 1,697,029. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $9.79. The firm has a market capitalization of $3.01 billion, a P/E ratio of 959.96 and a beta of 1.11. The firm has a fifty day simple moving average of $8.38 and a 200 day simple moving average of $8.01.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities analysts expect that Amneal Pharmaceuticals will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.